Continuous administration of ranibizumab with a port delivery system provides an alternative to frequent intravitreal ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

injections of anti-VEGF (ranibizumab) treatments. "The PDS was found to be well tolerated with the potential to reduce the treatment burden [the workload of healthcare caused by a chronic ...

In this study, 4300 patients received 0.3 or 0.5 mg of ranibizumab every 3 months after the initial series of three monthly injections. After the first 3 injections the mean visual acuity improved ...

Additionally, the prognosis of macular edema may help clinicians evaluate renal function, investigators reported ...

Susvimo was nonferior to intravitreal ranibizumab based on the change from baseline in distance best corrected visual acuity score. The Food and Drug Administration (FDA) has approved Susvimo ...

Susvimo, also known as ranibizumab injection, was first approved by the FDA for the treatment of wet age-related macular degeneration in 2021.

Basel, 04 February 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...